Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 2
1976 2
1977 2
1980 1
1981 1
1982 3
1983 2
1984 4
1985 2
1987 4
1988 6
1989 2
1990 6
1991 4
1992 2
1993 1
1994 3
1995 2
1996 3
1997 2
1998 7
1999 4
2000 2
2001 3
2002 3
2003 5
2004 8
2005 8
2006 9
2007 8
2008 5
2009 4
2010 6
2011 7
2012 4
2013 10
2014 10
2015 3
2016 8
2017 5
2018 4
2019 4
2020 12
2021 10
2022 10
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Childhood brain tumors: current management, biological insights, and future directions.
Pollack IF, Agnihotri S, Broniscer A. Pollack IF, et al. J Neurosurg Pediatr. 2019 Mar 1;23(3):261-273. doi: 10.3171/2018.10.PEDS18377. J Neurosurg Pediatr. 2019. PMID: 30835699 Free PMC article. Review.
Likewise, high-grade glioma, which for decades was considered a single high-risk entity, is now known to comprise multiple subsets of tumors that differ in terms of patient age, tumor location, and prognosis. ...Conversely, the majority of pilocytic astrocytomas appear to …
Likewise, high-grade glioma, which for decades was considered a single high-risk entity, is now known to comprise multiple subsets of …
EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma.
Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, Dangouloff-Ros V, Boddaert N, Hattingen E, Wiestler B, Clifford SC, Figarella-Branger D, Giangaspero F, Haberler C, Pietsch T, Pajtler KW, Pfister SM, Guzman R, Stummer W, Combs SE, Seidel C, Beier D, McCabe MG, Grotzer M, Laigle-Donadey F, Stücklin ASG, Idbaih A, Preusser M, van den Bent M, Weller M, Hau P. Franceschi E, et al. Lancet Oncol. 2019 Dec;20(12):e715-e728. doi: 10.1016/S1470-2045(19)30669-2. Lancet Oncol. 2019. PMID: 31797797 Review.
Our recommendations are a resource for professionals involved in the management of post-pubertal and adult patients with medulloblastoma, for patients and caregivers, and for health-care providers in Europe. The implementation of this guideline requires multidisciplinary s …
Our recommendations are a resource for professionals involved in the management of post-pubertal and adult patients with medulloblastoma, fo …
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, Niclou SP, Euskirchen P, Haberler C, Hegi ME, Brandner S, Le Rhun E, Rudà R, Sanson M, Tabatabai G, Sahm F, Wen PY, Wesseling P, Preusser M, van den Bent MJ. Capper D, et al. Neuro Oncol. 2023 May 4;25(5):813-826. doi: 10.1093/neuonc/noad008. Neuro Oncol. 2023. PMID: 36632791 Free PMC article.
For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. ...At present, targeted treatment for BRAF p.V600E alterations …
For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of th …
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma.
Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD. Donovan LK, et al. Nat Med. 2020 May;26(5):720-731. doi: 10.1038/s41591-020-0827-2. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341580 Free PMC article.
Recurrent medulloblastoma and ependymoma are universally lethal, with no approved targeted therapies and few candidates presently under clinical evaluation. Nearly all recurrent medulloblastomas and posterior fossa group A (PFA) ependymomas are located adjacent to and bath …
Recurrent medulloblastoma and ependymoma are universally lethal, with no approved targeted therapies and few candidates presently und …
Advances in Treatment of Diffuse Midline Gliomas.
Cacciotti C, Wright KD. Cacciotti C, et al. Curr Neurol Neurosci Rep. 2023 Dec;23(12):849-856. doi: 10.1007/s11910-023-01317-8. Epub 2023 Nov 3. Curr Neurol Neurosci Rep. 2023. PMID: 37921944 Review.
PURPOSE OF REVIEW: Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline structures of the central nervous system, including the thalamus, pons, and spinal cord. ...Herein, we review the complex features of this diseas …
PURPOSE OF REVIEW: Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline struc …
Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X, Ding C, Tan W, Zhang A. Liu X, et al. Pharmacol Ther. 2020 Jun;210:107516. doi: 10.1016/j.pharmthera.2020.107516. Epub 2020 Feb 24. Pharmacol Ther. 2020. PMID: 32105673 Review.
Medulloblastoma (MB) is the most common childhood malignant brain tumor, accounting for approximately 20% of all pediatric central nervous system tumors. ...More recent studies have indicated that up to seven molecular subgroups exist in childhood MB. Moreover, stud …
Medulloblastoma (MB) is the most common childhood malignant brain tumor, accounting for approximately 20% of all pediatric central ne …
Assessment of Puberty and Hypothalamic-Pituitary-Gonadal Axis Function After Childhood Brain Tumor Treatment.
Rosimont M, Kariyawasam D, Samara-Boustani D, Giani E, Beltrand J, Bolle S, Fresneau B, Puget S, Sainte-Rose C, Alapetite C, Pinto G, Touraine P, Piketty ML, Brabant S, Abbou S, Aerts I, Beccaria K, Bourgeois M, Roujeau T, Blauwblomme T, Rocco FD, Thalassinos C, Rigaud C, James S, Busiah K, Simon A, Bourdeaut F, Lemelle L, Guerrini-Rousseau L, Orbach D, Doz F, Dufour C, Grill J, Polak M, Briceño LG. Rosimont M, et al. J Clin Endocrinol Metab. 2023 Aug 18;108(9):e823-e831. doi: 10.1210/clinem/dgad097. J Clin Endocrinol Metab. 2023. PMID: 36810692
OBJECTIVE: To describe hypothalamic-pituitary-gonadal axis (HPGA) function in patients treated in childhood for a primary brain tumor more than 5 years earlier, in order to identify risk factors for HPGA impairment. ...Awareness that onset can be delayed is essential to gu …
OBJECTIVE: To describe hypothalamic-pituitary-gonadal axis (HPGA) function in patients treated in childhood for a primary brain tumor …
Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD, Hoffman SE, Kappel AD, Valdes PA, Essayed W, Klinger NV, Kang KD, Totsch SK, Olsen HE, Schlappi CW, Filipski K, Gessler FA, Baird L, Filbin MG, Hashizume R, Becher OJ, Friedman GK. Bernstock JD, et al. Oncoimmunology. 2022 Sep 26;11(1):2124058. doi: 10.1080/2162402X.2022.2124058. eCollection 2022. Oncoimmunology. 2022. PMID: 36185807 Free PMC article. Review.
Diffuse midline gliomas (DMG) are a highly aggressive and universally fatal subgroup of pediatric tumors responsible for the majority of childhood brain tumor deaths. Median overall survival is less than 12 months with a 90% mortality rate at 2 years from diagnosis. ...Thi …
Diffuse midline gliomas (DMG) are a highly aggressive and universally fatal subgroup of pediatric tumors responsible for the majority of …
Unique molecular, clinical, and treatment aspects of gliomas in adolescents and young adults: a review.
Lim-Fat MJ, Das S. Lim-Fat MJ, et al. J Neurosurg. 2023 May 26;139(6):1619-1627. doi: 10.3171/2023.4.JNS221800. Print 2023 Dec 1. J Neurosurg. 2023. PMID: 37243561 Review.
Adolescent and young adult (AYA) patients with glioma have historically had poorer outcomes than similar patients of younger or older age, a disparity thought to be attributable to the social and economic challenges faced by this group in the transition from childhood …
Adolescent and young adult (AYA) patients with glioma have historically had poorer outcomes than similar patients of younger or older …
Clinical Features, Treatment and Outcome of Childhood Glial Tumors.
Kara B, Ertan K, Karabagli P, Karabagli H, Yavas G, Caglayan AO, Koksal Y. Kara B, et al. Turk Neurosurg. 2022;32(1):135-142. doi: 10.5137/1019-5149.JTN.34801-21.2. Turk Neurosurg. 2022. PMID: 34751424 Free article.
The most common tumor location was supratentorial (n=42, 57.5%), while midline glioma was detected in seven patients. The 5-year overall survival (OS) rate of all glial tumors, astrocytoma, and ependymoma was 42%, 40%, and 55%, respectively. ...
The most common tumor location was supratentorial (n=42, 57.5%), while midline glioma was detected in seven patients. The 5-year over …
215 results